Francesco Peyronel

TL;DR: The first-line treatment of IgG4-RD is based on glucocorticoids, which are usually efficacious, but B cell depletion induced by rituximab has also been found to induce remission in steroid-resistant disease or has been used as steroid-sparing agent for relapsing disease.

TL;DR: Serum IgG4 levels are high in a minority of CP patients and do not identify specific clinical or prognostic subgroups; only a higher frequency of extra-retroperitoneal lesions is found in high-IgG4 patients.

TL;DR: In critically ill patients with AKI, quadriceps muscle thickness assessment based on US is unbiased, although it occurs with a minor loss of precision compared to CT.

TL;DR: Rituximab is tested in CP patients without evidence of IgG4-RD who had relapsing/refractory disease or contraindications to standard-dose glucocorticoids, and online supplementary methods describe the diagnostic and follow-up procedures, the definitions of remission and refractory, and the statistical analysis.

TL;DR: The role of fibrocytes, circulating precursors of tissue fibroblasts, in patients with CP are explored to explore the pathogenic mechanisms leading to tissue accumulation and activation of fibROblasts.